Contact Lens & Anterior Eye
Volume 35, Issue 1 , Pages 9-16 , February 2012

A review of non-pharmacological and pharmacological management of seasonal and perennial allergic conjunctivitis

References 

  1. Williams H, Stewart A, von Mutius E, Cookson W, Anderson HR. Is eczema really on the increase worldwide?. Journal of Allergy and Clinical Immunology. 2008;121:947
  2. Asher MI, Montefort S, Bjorksten B, Lai CKW, Strachan DP, Weiland SK, et al. Worldwide time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and eczema in childhood: ISAAC Phases One and Three repeat multi-country cross-sectional surveys. The Lancet. 2006;368(9537):733–743
  3. Savage J, Roy D. Allergic rhinitis: an update. Journal of the Royal Society for the Promotion of Health. 2005;125(4):172–175
  4. Romagnani S. The increased prevalence of allergy and the hygiene hypothesis: missing immune deviation, reduced immune suppression, or both?. Immunology. 2004;112(3):352–363
  5. Cohet C, Cheng S, MacDonald C, Baker M, Foliaki S, Huntington N, et al. Infections, medication use, and the prevalence of symptoms of asthma, eczema and rhinitis in childhood. Journal of Epidemiology and Community Health. 2004;58(10):852–857
  6. Bresciani M, Parisi C, Manghi G, Bonini S. The hygiene hypothesis: does it function worldwide?. Current Opinion in Allergy and Clinical Immunology. 2005;5:147–150
  7. Linneberg A, Jorgenson T, Nielson NH, Madsen F, Frolund L, Driksen A. The prevalence of skin-test-positive allergic rhinitis in Danish adults: two cross-sectional surveys 8 years apart. The Copenhagen Allergy Study. Allergy. 2000;55(8):767–772
  8. D’Amato G, Cecchi L, Bonini S, Nunes C, Annesi-Maesano I, Behrendt H, et al. Allergenic pollen and pollen allergy in Europe. Allergy. 2007;62(9):976–990
  9. Alcazar P, Carinanos P, De Castro C, Guerra F, Moreno C, Dominguez-Vilches E, et al. Airborne plane-trees (platanus hispanica) pollen distribution in the city of Cordoba, south western Spain, and possible implications on pollen allergy. Journal of Investigative Allergology and Clinical Immunology. 2004;14(3):238–243
  10. Abelson MB, Leonardi A, Smith L. The mechanisms, diagnosis and treatment of allergy. Review of Ophthalmology. 2002;9(4):74–84
  11. Leonardi A. Emerging drugs for ocular allergy. Expert Opinion on Emerging Drugs. 2005;10(3):505–520
  12. Wolffsohn JS, Naroo SA, Gupta N, Emberlin J. Prevalence and impact of ocular allergy in the population attending UK optometric practice. Contact Lens and Anterior Eye, in press.
  13. Abelson MB, Schaefer K. Conjunctivitis of allergic origin: immunologic mechanisms and current approaches to therapy. Survey of Opthalmology. 1993;38(S):115
  14. Friedlaender MH. Conjunctivitis of allergic origin: clinical presentation and differential diagnosis. Survey of Ophthalmology. 1993;38(S):105
  15. Bielory L. Allergic and immunologic disorders of the eye Part II: ocular allergy. Journal of Allergy and Clinical Immunology. 2000;106(6):1019–1032
  16. Wilson FM. Adverse external effects of topical ophthalmic medications. Survey of Ophthalmology. 1979;24(2):57–88
  17. Schuman JS. Antiglaucoma medications: a review of safety and tolerability issues related to their use. Clinical Therapeutics. 2000;22(2):167–208
  18. Collet E, Castelain M, Milpied B. Contact allergic reactions on the eyes and eyelids. Revue Francaise D Allergologie. 2011;51(3):318–322
  19. Helm CJ, Holland GN. Ocular tuberculosis. Survey of Ophthalmology. 1993;38(3):229–256
  20. Donshik PC, Ehlers WH, Ballow M. Giant papillary conjunctivitis. Immunology and Allergy Clinics of North America. 2008;28(1):83–103
  21. Bielory L. Ocular allergy treatment. Immunology and Allergy Clinics of North America. 2008;28(1):189–224
  22. Cox L. Allergic conjunctivitis. Allergy and Clinical Immunology International-Journal of the World Allergy Organisation. 2007;19:4–8
  23. Berdy GJ, Berdy SS. Ocular allergic disorders: disease entities and differential diagnoses. Current Allergy and Asthma Reports. 2009;9(4):297–303
  24. Bielory L. Ocular allergy overview. Immunology and Allergy Clinics of North America. 2008;28(1):1–23
  25. Bonini S, Coassin M, Arroni S, Lambiase A. Vernal keratoconjunctivitis. Eye. 2004;18(4):345–351
  26. Chigbu DI. The management of allergic eye disease in primary care. Contact Lens and Anterior Eye. 2009;32(6):260–272
  27. Buckley RJ. Allergic eye disease – a clinical challenge. Clinical and Experimental Allergy. 1998;28(6):39–43
  28. Bielory L. Allergic diseases of the eye. Medical Clinics of North America. 2006;90(1):129–148
  29. Pitt AD, Smith AF, Lindsell L, Voon LW, Rose PW, Bron AJ. Economic and quality of life impact of seasonal allergic conjunctivitis in Oxfordshire. Ophthalmic Epidemiology. 2004;11(1):17–33
  30. Smith AF, Pitt AD, Rodruiguez AE, Alio JL, Marti N, Teus M, et al. The economic and quality of life impact of seasonal allergic conjunctivitis in Spanish setting. Ophthalmic Epidemiology. 2005;12(4):233–242
  31. Palmares J, Delgado L, Cidade M, Quadrado MJ, Filipe HP. Allergic conjunctivitis: a national cross-sectional study of clinical characteristics and quality of life. European Journal of Ophthalmology. 2010;20(2):257–264
  32. Hingorani M, Lightman S. Therapeutic options in ocular allergic disease. Drugs. 1995;50(2):208–221
  33. Joss J, Craig T. Seasonal allergic conjunctivitis. Drugs of Today. 1998;34(3):259–265
  34. Bielory BP, Perez VL, Bielory L. Treatment of seasonal allergic conjunctivitis with ophthalmic corticosteroids: in search of the perfect ocular corticosteroids in the treatment of allergic conjunctivitis. Current Opinion in Allergy and Clinical Immunology. 2010;10(5):469–477
  35. Bacon AS, Ahluwalia P, Irani AM, Schwartz LB, Holgate ST, Church MK, et al. Tear and conjunctival changes during the allergen-induced early- and late-phase responses. Journal of Allergy and Clinical Immunology. 2000;106(5):948–954
  36. Choi SH, Bielory L. Late-phase reaction in ocular allergy. Current Opinion in Allergy and Clinical Immunology. 2008;8(5):438–444
  37. Ono SJ, Abelson MB. Allergic conjunctivitis: update on pathophysiology and prospects for future treatment. Journal of Allergy and Clinical Immunology. 2005;115(1):118–122
  38. Hodges MG, Kean-Myers AM. Classification of ocular allergy. Current Opinion in Allergy and Clinical Immunology. 2007;7(5):424–428
  39. Leonardi A, Motterle L, Bortolotti M. Allergy and the eye. Clinical and Experimental Immunology. 2008;153:17–21
  40. Stahl JL, Cook EB, Barney NP, Graziano FM. Pathophysiology of ocular allergy: the roles of conjunctival mast cells and epithelial cells. Current Allergy and Asthma Reports. 2002;2(4):332–339
  41. Bonini ST, Bonini SE, Berruto A, Tomassini M, Carlesimo S, Bucci MG, et al. Conjunctival provocation test as a model for the study of allergy and inflammation in humans. International Archives of Allergy and Applied Immunology. 1989;88:144
  42. Ciprandi G, Buscaglia S, Canonica GW. Management of allergic conjunctivitis. Clinical Immunotherapeutics. 1996;5(5):374–391
  43. Friedlaender M. Overview of ocular allergy treatment. Current Allergy and Asthma Reports. 2001;1(4):375–379
  44. Veys J. Managing the contact lens wearing allergy sufferer. Optician. 2004;5950(227):22–26
  45. Gotzche PC, Johansen HK. House dust mite control measures for asthma: systematic review. Allergy. 2008;63(6):646–659
  46. Sheikh A, Hurwitz B, Nurmatov U, van Schayck CP. House dust mite avoidance measures for perennial allergic rhinitis. Cochrane Database of Systematic Reviews. 2010;7:CD001563
  47. Eggleston PA, Wood RA. Management of allergies to animals. Asthma Proceedings. 1992;13(6):289–292
  48. Bush RK. Indoor allergens, environmental avoidance and allergic respiratory disease. Allergy and Asthma Proceedings. 2008;29(6):575–579
  49. Wong AHC, Barg SSN, Leung AKC. Seasonal and perennial allergic conjunctivitis. Recent Patents on Inflammation and Allergy Drugs Discovery. 2009;3(2):118–127
  50. Schultz BL. Pharmacology of ocular allergy. Current Opinion in Allergy and Clinical Immunology. 2006;6(5):383–389
  51. Leino M, Ennevaara K, Latvala AL, Nordgren P, Posti AM, Suves R, et al. Double blind group comparative study of 2-percent nedocromil sodium eye drops with 2-percent sodium cromoglycate and placebo eye drops in the treatment of seasonal allergic conjunctivitis. Clinical and Experimental Allergy. 1992;22(10):929–932
  52. Blumenthal M, Casale T, Dockhorn R, Jarmoszuk I, Kaiser H, Smith R, et al. Efficacy and safety of nedocromil sodium ophthalmic solution in the treatment of seasonal allergic conjunctivitis. American Journal of Ophthalmology. 1992;113(1):56–63
  53. Cerqueti PM, Ricca V, Tosca MA, Buscaglia S, Ciprandi G. Lodoxamide treatment of allergic conjunctivitis. International Archives of Allergy and Immunology. 1994;105(2):185–189
  54. Owen CG, Shah A, Henshaw K, Smeeth L, Sheikh A. Topical treatments for allergic conjunctivitis: systematic review and meta-analysis of efficacy and effectiveness. British Journal of General Practice. 2004;54(503):451–456
  55. BMJ Group and Pharmaceutical Press. British National Formulary 61. 11. Eye. 11.4 Corticosteroids and other anti-inflammatory preparations; 2010. Available from: www.bnf.org [accessed 11.04.2011].
  56. Juniper EF, Guyatt GH, Ferrie PJ, King DR. Sodium cromoglycate eye drops: regular versus as needed use in seasonal allergic conjunctivitis. Journal of Allergy and Clinical Immunology. 1994;94(1):36–43
  57. Fahy GT, Easty DL, Collum LM, Benedict-Smith A, Hillery M, Parsons DG. Randomised double masked trial of lodoxamide and sodium cromoglycate in allergic eye disease. European Journal of Ophthalmology. 1992;2:144
  58. Collum LMT, Fitzsimon S, Hillery M, Collum A, Power WJ, Pelikan Z, et al. Twice daily 4% sodium cromoglycate vs 2% sodium cromoglycate used four times daily in seasonal (grass pollen) allergic conjunctivitis. Documenta Ophthalmologica. 1992;82(3):267–277
  59. Bielory L, Ghafoor S. Histamine receptors and the conjunctiva. Current Opinion in Allergy and Clinical immunology. 2005;5(5):437–440
  60. Miller J, Wolf EH. Antazoline phosphate and naphazoline hydrochloride, singly and in combination for the treatment of allergic conjunctivitis – a controlled, double blind clinical trial. Annals of Allergy. 1975;35(2):81–86
  61. Ciprandi G, Buscaglia S, Catrullo A, Pesce G, Fiorino N, Montagna P, et al. Azelastine eye drops reduce and prevent allergic conjunctival reaction and exert anti-allergic activity. Clinical and Experimental Allergy. 1997;27(2):182–191
  62. Giede-Tuch C, Westhoff M, Zarth A. Azelastine eye drops in seasonal allergic conjunctivitis or rhinoconjunctivitis – a double blind, randomised, placebo-controlled study. Allergy. 1998;53(9):857–862
  63. Netland PA, Leahy C, Krenzer KL. Emedastine ophthalmic solution 0.05% versus levocabastine ophthalmic suspension 0.05% in the treatment of allergic conjunctivitis in the conjunctival allergen challenge model. American Journal of Ophthalmology. 2000;130(6):717–723
  64. Williams PB, Crandall E, Sheppard JD. Azelastine hydrochloride, a dual acting anti-inflammatory ophthalmic solution, for treatment of allergic conjunctivitis. Clinical Ophthalmology. 2010;4:993–1001
  65. Canonica GW, Ciprandi G, Petzold U, Kolb C, Ellers-Lenz B, Hermann R. Topical azelastine in perennial allergic conjunctivitis. Current Medical Research and Opinion. 2003;19(4):321–329
  66. Bielory L, Lien KW, Bigelson S. Efficacy and tolerability of newer antihistamines in the treatment of allergic conjunctivitis. Drugs. 2005;65(2):215–228
  67. The electronic Medicines Compendium (eMC). Optrex bloodshot eye drops – summary of product characteristics (SPC); 2010. Available from: http://www.medicines.org.uk/EMC/medicine/23394/SPC/Optrex+Bloodshot+Eye+Drops/ [accessed 11.04.11].
  68. Smith JP, Lanier BQ, Tremblay N, Ward RL, Defaller JM. Treatment of allergic conjunctivitis with ocular decongestants. Current Eye Research. 1982;2(2):141–147
  69. Lanier BQ, Tremblay N, Smith JP, Defaller JM. A double masked comparison of ocular decongestants as therapy for allergic conjunctivitis. Annals of Allergy. 1983;50(3):174–177
  70. Abelson MB, Paradis A, George MA, Smith LM, Maguire L, Burns R. Effects of vasocon-A in the allergen challenge model of acute allergic conjunctivitis. Archives of Ophthalmology. 1990;108(4):520–524
  71. Abelson MB, Allansmith MR, Friedlaender MH. Effects of topically applied ocular decongestant and antihistamine. American Journal of Ophthalmology. 1980;90:254
  72. Bielory L. Ocular allergy guidelines – a practical treatment algorithm. Drugs. 2002;62(11):1611–1634
  73. Bielory L. Role of antihistamines in ocular allergy. American Journal of Medicine. 2002;113:34–37
  74. Ousler GW, Workman DA, Torkildsen GL. An open label, investigator-masked, crossover study of the ocular drying effects of two antihistamines, topical epinastine and systemic loratadine, in adult volunteers with seasonal allergic conjunctivitis. Clinical Therapeutics. 2007;29(4):611–616
  75. Abelson MB, Kaplan AP. A randomized, double-blind, placebo-controlled comparison of emedastine 0.05% ophthalmic solution with loratadine 10mg and their combination in the human conjunctival allergen challenge model. Clinical Therapeutics. 2002;24(3):445–456
  76. Crampton HJ. Comparison of ketotifen fumarate ophthalmic solution alone, desloratadine alone, and their combination for inhibition of the signs and symptoms of seasonal allergic rhinoconjunctivitis in the conjunctival allergen challenge model: a double-masked, placebo- and active-controlled trial. Clinical Therapeutics. 2003;25(7):1975–1987
  77. Lanier BQ, Gross RD, Marks BB, Cockrum PC, Juniper EF. Olopatadine ophthalmic solution adjunctive to loratadine compared with loratadine alone in patients with active seasonal allergic conjunctivitis symptoms. Annals of Allergy Asthma and Immunology. 2001;86(6):641–648
  78. Abelson MB. Evaluation of olopatadine, a new ophthalmic antiallergic agent with dual activity, using the conjunctival allergen challenge model. Annals of Allergy Asthma and Immunology. 1998;81(3):211–218
  79. Avunduk AM, Tekelioglu Y, Turk A, Akyol N. Comparison of the effects of ketotifen fumarate 0.025% and olopatadine HCl 0.1% ophthalmic solutions in seasonal allergic conjunctivitis: a 30-day, randomized, double-masked, artificial tear substitute-controlled trial. Clinical Therapeutics. 2005;27(9):1392–1402
  80. Kidd M, McKenzie SH, Steven I, Cooper C, Lanz R. Efficacy and safety of ketotifen eye drops in the treatment of seasonal allergic conjunctivitis. British Journal of Ophthalmology. 2003;87(10):1206–1211
  81. Abelson MB, Gomes P, Crampton HJ, Schiffman RM, Bradford RR, Whitcup SM. Efficacy and tolerability of ophthalmic epinastine assessed using the conjunctival antigen challenge model in patients with a history of allergic conjunctivitis. Clinical Therapeutics. 2004;26(1):35–47
  82. Swamy BN, Chilov M, McClellan K, Petsoglou C. Topical non-steroidal anti-inflammatory drugs in allergic conjunctivitis: meta-analysis of randomized trial data. Ophthalmic Epidemiology. 2007;14(5):311–319
  83. Tauber J, Raizman MB, Ostrov CS, Laibovitz RA, Abelson MB, Betts JG, et al. A multicenter comparison of the ocular efficacy and safety of diclofenac 0.1% solution with that of ketorolac 0.5% solution in patients with acute seasonal allergic conjunctivitis. Journal of Ocular Pharmacology and Therapeutics. 1998;14(2):137–145
  84. Friedlaender MH. Management of ocular allergy. Annals of Allergy Asthma and Immunology. 1995;75(3):212–222
  85. Bielory L, Friedlaender MH. Allergic conjunctivitis. Immunology and Allergy Clinics of North America. 2008;28(1):43–58
  86. Dell SJ, Lowry GM, Northcutt JA, Howes J, Novack GD, Hart K. A randomized, double-masked, placebo-controlled parallel study of 0.2% loteprednol etabonate in patients with seasonal allergic conjunctivitis. Journal of Allergy and Clinical Immunology. 1998;102(2):251–255
  87. Ebihara N, Ohashi Y, Uchio E, Okamoto S, Kumagai N, Shoji J, et al. A large, prospective observational study of novel cyclosporine 0.1% aqueous ophthalmic solution in the treatment of severe allergic conjunctivitis. Journal of Ocular Pharmacology and Therapeutics. 2009;25(4):365–371
  88. Miyazaki D, Tominaga T, Kakimaru-Hasegawa A, Nagata Y, Hasegawa J, Inoue Y. Therapeutic effects of tacrolimus ointment for refractory ocular surface inflammatory diseases. Ophthalmology. 2008;115(6):988–992
  89. Pradalier A, Basset D, Claudel A, Couturier P, Wessel F, Galvain S, et al. Sublingual-swallow immunotherapy (SLIT) with a standardised five-grass-pollen extract (drops and sublingual tablets) versus placebo in seasonal rhinitis. Allergy. 1999;54(8):819–828
  90. Bielory L, Mongia A. Current opinion on immunotherapy for ocular allergy. Current Opinion in Allergy and Clinical Immunology. 2002;2(5):447–452
  91. Skoner D, Gentile D, Bush R, Fasano MB, McLaughlin A, Esch RE. Sublingual immunotherapy in patients with allergic rhinoconjunctivitis caused by ragweed pollen. Journal of Allergy and Clinical Immunology. 2010;125(3):660–666
  92. Lemp MA. Contact lenses and associated anterior segment disorders: dry eye, blepharitis and allergy. Ophthalmology Clinics of North America. 2003;16(3):463–469
  93. Krohn JC. A menu of lens wear options for allergy prone patients. Review of Optometry. 2000;137(4):77–80
  94. Wolffsohn JS, Emberlin JC. Role of contact lenses in relieving ocular allergy. Contact Lens and Anterior Eye, in press.
  95. Lemp MA. Contact lenses and allergy. Current Opinion in Allergy and Clinical Immunology. 2008;8(5):457–460
  96. Shovlin JP, DePaolis M, Winn S. Drops to prevent drop outs. Review of Optometry. 2000;137(4):69–75
  97. Brodsky M, Berger WE, Butrus S, Epstein AB, Irkec M. Evaluation of comfort using olopatadine hydrochloride 0.1% ophthalmic solution in the treatment of allergic conjunctivitis in contact lens wearers compared to placebo using the conjunctival allergen challenge model. Eye and Contact Lens. 2003;29:113–116
  98. Borazan M, Karalezli A, Akova YA, Akman A, Kiyici H, Erbek SS. Efficacy of olopatadine HCI 0.1%, ketotifen fumarate 0.025%, epinastine HCI 0.05%, emedastine 0.05% and fluorometholone acetate 0.1% ophthalmic solutions for seasonal allergic conjunctivitis: a placebo-controlled environmental trial. Acta Ophthalmologica. 2009;87(5):549–554
  99. Lanier BQ, Finegold I, D’Arienzo P, Granet D, Epstein AB, Ledgerwood GL. Clinical efficacy of olopatadine vs epinastine ophthalmic solution in the conjunctival allergen challenge model. Current Medical Research and Opinion. 2004;20(8):1227–1233
  100. Mah FS, Rosenwasser LJ, Townsend WD, Greiner JV, Bensch G. Efficacy and comfort of olopatadine 0.2% versus epinastine 0.05% ophthalmic solution for treating itching and redness induced by conjunctival allergen challenge. Current Medical Research and Opinion. 2007;23(6):1445–1452
  101. Abelson MB, Loeffler O. Conjunctival allergen challenge: models in the investigation of ocular allergy. Current Allergy and Asthma Reports. 2003;3(4):363–368
  102. Friedlaender MH. Conjunctival provocation testing: overview of recent clinical trials in ocular allergy. Current Opinion in Allergy and Clinical Immunology. 2002;2(5):413–417
  103. Ousler GW, Gomes PJ, Welch D, Abelson MB. Methodologies for the study of ocular surface disease. Ocular Surface. 2005;3(3):143–154
  104. Spangler DL, Bensch G, Berdy GJ. Evaluation of the efficacy of olopatadine hydrochloride 0.1% ophthalmic solution and azelastine hydrochloride 0.05% ophthalmic solution in the conjunctival allergen challenge model. Clinical Therapeutics. 2001;23(8):1272–1280
  105. Berdy GJ, Spangler DL, Bensch G, Berdy SS, Brusatti RC. A comparison of the relative efficacy and clinical performance of olopatadine hydrochloride ophthalmic solution 0.1% and ketotifen fumarate 0.025% ophthalmic solution in the conjunctival allergen challenge model. Clinical Therapeutics. 2000;22(7):826–833
  106. Abelson MB, Greiner JV. Comparative efficacy of olopatadine 0.1% ophthalmic solution versus levocabastine 0.05% ophthalmic suspension using the allergen challenge model. Current Medical Research and Opinion. 2004;20(12):1953–1958
  107. Ciprandi G, Turner D, Gross RD. Double masked, randomised, parallel-group study comparing olopatadine 0.1% ophthalmic solution with cromolyn sodium 2% and levocabastine 0.05% ophthalmic preparations in children with seasonal allergic conjunctivitis. Current Therapeutic Research. 2004;65(2):186–199
  108. Alexander M, Allegro S, Hicks A. Efficacy and acceptability on nedocromil sodium 2% and olopatadine hydrochloride 0.1% in perennial allergic conjunctivitis. Advances in Therapy. 2000;17(3):140–147
  109. D’Arienzo PA, Leonardi A, Bensch G. Randomised, double-masked, placebo-controlled comparison of the efficacy of emedastine difumarate 0.05% ophthalmic solution and ketotifen fumarate 0.025% ophthalmic solution in the conjunctival challenge model. Clinical Therapeutics. 2002;24(3):409–416
  110. Figus M, Fogagnolo P, Lazzeri S, Capizzi F, Romagnoli M, Canovetti A, et al. Treatment of allergic conjunctivitis: results of a 1-month, single-masked randomized study. European Journal of Ophthalmology. 2010;20(5):811–818
  111. Katelaris CH, Bielory L. Evidence-based study design in ocular allergy trials. Current Opinion in Allergy and Clinical Immunology. 2008;8(5):448–488

PII: S1367-0484(11)00124-X

doi: 10.1016/j.clae.2011.08.009

Contact Lens & Anterior Eye
Volume 35, Issue 1 , Pages 9-16 , February 2012

Article Tools